UBS/CALL/IDORSIA/3.002/0.5/20.12.24 | Market Closed - Swiss Exchange 16:20:00 03/07/2024 BST | ||
| 0.39 CHF | -4.88% |
|
| 3 months | -40.00% | ||
| 6 months | -17.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 0.39 | -4.88% |
Delayed Quote Swiss Exchange
Last update July 03, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | UBS |
| YIDIQU | |
| ISIN | CH1292037038 |
| Date issued | 05/10/2023 |
| Strike | 3.002 CHF |
| Maturity | 20/12/2024 (170 Days) |
| Parity | 2 : 1 |
| Emission price | 0.33 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.81 CHF |
|---|---|
| Lowest since issue | 0.25 CHF |
| Spread | 0.06 CHF |
| Spread % | 15.38% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.28
CHF
Average target price
1.692
CHF
Spread / Average Target
-25.77%
- Stock Market
- Warrants
- YIDIQU Warrant
